From: Modification of mesenchymal stem cells for cartilage-targeted therapy
Ligand | Target | Application | Ref |
---|---|---|---|
Cartilage penetrating cationic peptide (CPC) | Fixed charge density (FCD) of cartilage | Rapid penetration in full cartilage, high absorption, and 7-day retention of CPC + 14 | [78] |
Supercharged green fluorescent proteins (GFPs) | Cartilage | Rapid transport into full-thickness cartilage and chondrocyte | [79] |
CDP-11R | Cartilage | Accumulation in the cartilage after systemic intravenous injection; alleviation 0f joint inflammation and off-target toxicity | [73] |
CBP peptide: LRELHLNNNC | Collagens | Targeting the extracellular matrix of inflamed tissues | [80] |
PIGF2_123–144 | ECM, collagen type II | Improved cartilage adhesion of MSCs | |
CAP peptide: DWRVIIPPRPSA | Chondrocytes | Plasmid DNA and exosome target delivery | |
Aggrecan-binding peptides peptide: RLDPTSYLRTFW, HDSQLEALIKFM | Aggrecan | Binding to chondrocytes and extracellular matrix | [72] |
Type II collagen binding peptide: WYRGRL | Collagen type 2 (CII) | Deep zone retention, increased half-life and retention in the cartilage | |
P15-1 peptide: STMMSRSHKTRSHHV | Hyaluronan (HA) | Inhibition of chondrocytes inflammation | [84] |
Monoclonal antibody (mAbCII) | Collagen type 2 | Enhanced collagen II binding and MMP-13 siRNA delivery for OA therapy | [85] |
Avimer M26 | Collagen II | Enhanced cartilage retention time | [86] |
Multi-arm Avidin (mAv) | Aggrecan-associated glycosaminoglycans (GAGs) | Penetration through the full thickness of cartilage |